No Data
No Data
Australian Clinical Labs Target Price Cut 6.9% to A$3.35/Share by Citi>ACL.AU
Australian Clinical Labs Target Price Cut 6.9% to A$3.35/Share by Citi>ACL.AU
2 ASX 300 Shares Crashing up to 12% on Earnings Updates
Listed below are two ASX 300 shares that are being sold off following the release of their respective releases.
Australian Clinical Labs Slashes Interim Dividend as Underlying H1 FY24 EPS Falls 49%
Australian Clinical Labs (ASX:ACL) reported Wednesday that its underlying earnings per share in the six-month period ended Dec. 31, 2023, were down 49% year over year to AU$0.0511. Statutory EPS fell
Australian Clinical Labs Interim Dividend 3 Australian Cents/Security
Australian Clinical Labs Interim Dividend 3 Australian Cents/Security
Australian Clinical Labs 1H Revenue A$337.3 Million, Down 6.4%
Australian Clinical Labs 1H Revenue A$337.3 Million, Down 6.4%
Medicare Levy Change: 1.2 Million Aussies to Get Extra Tax Boost
Millions of Aussies will be able to avoid or pay a lower Medicare levy under a major change announced by the government.
No Data